Study Supports MS Drug Withdrawn from Market Story aired: Tuesday, March 07, 2006
The latest edition of the New England Journal of Medicine features three new studies about a drug that has been withdrawn from the market. Publication comes days before the Food and Drug Administration is scheduled to start hearings on whether to allow sales of Tysabri, which was used to treat people with multiple sclerosis.
The Cambridge, MA-based company, Biogen Idec, withdrew its drug from the market last year after two patients developed a lethal brain disease.
Guests:
WBUR Health and science reporter Allan Coukell
In order to listen to our archived recordings, you must use the Real Audio Player, available for free at www.real.com
With sponsorship from: The leading developer and supplier of technical computing software in the world.
